Silibinin ameliorates anxiety/depression-like behaviors in amyloid β-treated rats by upregulating BDNF/TrkB pathway and attenuating autophagy in hippocampus
Male
Neurons
Psychotropic Drugs
0303 health sciences
Amyloid beta-Peptides
Dose-Response Relationship, Drug
Depression
Brain-Derived Neurotrophic Factor
Anxiety
Hippocampus
Peptide Fragments
3. Good health
Rats, Sprague-Dawley
Disease Models, Animal
03 medical and health sciences
Neuroprotective Agents
Piperidines
Alzheimer Disease
Indans
Autophagy
Animals
Receptor, trkB
Donepezil
DOI:
10.1016/j.physbeh.2017.07.023
Publication Date:
2017-07-19T22:00:17Z
AUTHORS (11)
ABSTRACT
Depression is one of the most frequent psychiatric disorders of Alzheimer's disease (AD). Depression and anxiety are associated with increased risk of developing AD. Silibinin, a flavonoid derived from milk thistle (Silybum marianum), has been used as a hepato-protectant in the clinical treatment of liver diseases. In this study, the effect of silibinin on Aβ-induced anxiety/depression-like behaviors in rats was investigated. Silibinin significantly attenuated anxiety/depression-like behaviors caused by Aβ1-42-treatment as shown in tail suspension test (TST), elevated plus maze (EPM) and forced swimming tests (FST). Moreover, silibinin was able to attenuate the neuronal damage in the hippocampus of Aβ1-42-injected rats. Silibinin-treatment up-regulated the function through BDNF/TrkB pathway and attenuated autophagy in the hippocampus. Our study provides a new insight into the protective effects of silibinin in the treatment of anxiety/depression.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (56)
CITATIONS (94)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....